Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL

Trial Profile

Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 23 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top